Menu Search Account

LegiStorm

Get LegiStorm App Visit Product Demo Website
» Get LegiStorm App
» Get LegiStorm Pro Free Demo

Opioid Use Disorder: Treatment with Injectable and Implantable Buprenorphine

  Premium   Download PDF Now (21 pages)
Report Type Reports and Testimonies
Report Date Aug. 4, 2020
Release Date Aug. 4, 2020
Report No. GAO-20-617
Summary:

Treatment for opioid use disorder may involve buprenorphine—a drug that can reduce or eliminate withdrawal symptoms and prevent relapse.

We reviewed the use of long-acting injectable and implantable forms of buprenorphine for opioid use disorder. These forms release the drug over 1- or 6-month periods respectively.

Providers issued about 7,250 prescriptions for injectable or implantable buprenorphine in FY 2019.

Providers and pharmacy representatives said there is a low risk of these forms of the drug being diverted to the illegal marketplace.

Buprenorphine may be injected into the abdomen or implanted in the upper arm.

figure of injections, implants

« Return to search Government Accountability Office reports